|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> 氘可来昔替尼>> 市场分析报告 |
氘可来昔替尼市场分析报告 |
|
TYK2 kinase inhibitors - Pipeline Insight, 2022 ... allosteric inhibitor of tyrosine kinase 2 (Tyk2). Deucravacitinib is being studied in multiple immune-mediated ... disease. Bristol Myers Squibb is evaluating deucravacitinib in Phase 3 clinical studies in psoriasis. Brepocitinib ... Psoriasis Treatment Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type ... is expected to slow to 3.5%–5% CAGR. Deucravacitinib (Sotyktu; Bristol Myers Squibb): ... medications, though competition from deucravacitinib is expected to challenge future growth ... for oral agents like deucravacitinib. Biologic Penetration in Emerging ... Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY According to the recently published report 'Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 ... Janus Kinase (JAK) Inhibitor Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application ... . Saudi Arabia's localization initiatives enhance deucravacitinib availability for psoriatic arthritis, while ... synergies. Bristol-Myers Squibb: Sotyktu (deucravacitinib) reached USD 0.2–0.3 billion in 2024, with ... Psoriatic arthritis - Pipeline Insight, 2021 ... : Bristol-Myers Squibb BMS-986165 (Deucravacitinib) is the first and only novel ... Active Pharmaceutical Ingredients (API) Market Size, Share, Trends and Forecast by Drug Type, Type of Manufacturer, Type of Synthesis, Therapeutic Application, and Region, 2025-2033 ... 's first allosteric inhibitor of TYK2, Sotyktu (deucravacitinib), was approved for the treatment ... Global Oral TYK2 Inhibitor Market Research Report 2025(Status and Outlook) ... giants like Bristol-Myers Squibb (deucravacitinib) and emerging biotech firms developing ... Global TYK2 Allosteric Inhibitor Market Research Report 2025(Status and Outlook) ... players like Bristol Myers Squibb (deucravacitinib) leading clinical development. Increasing R&D investments ... Global TYK2 Single-target Inhibitor Market Research Report 2025(Status and Outlook) ... , including Bristol-Myers Squibb (with deucravacitinib, the first FDA-approved TYK2 ... |